A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary) ; Regorafenib
- Indications Colorectal cancer
- Focus Therapeutic Use
- 15 Mar 2018 Status changed from suspended to discontinued.
- 05 Jan 2018 Status changed from recruiting to suspended.
- 18 Oct 2016 New trial record